Science
Scroll to learn more
Compelling preclinical and clinical research conducted at Georgetown University by KeifeRx’s co-founder, Charbel Moussa, MBBS, Ph.D., has demonstrated the ability of approved kinase inhibitor Nilotinib to cross the blood brain barrier in humans, enable toxic protein clearance, and show cognitive improvement in human trials.
The Science Behind KeifeRx
KeifeRx is building upon this extensive clinical experience in neurodegenerative diseases to advance a next generation of novel kinase Inhibitors that attack neurodegenerative diseases at their root cause. Our drugs candidates restore autophagy and attack the three pillars of neurodegenerative diseases; microglial-mediated neuroinflammation, toxic protein build up and vascular damage while restoring cognition.
Our lead asset is KFRX03, a first-in-class, small molecule kinase inhibitor for the treatment of Alzheimer’s disease that is highly brain penetrant with strong target engagement and a dose dependent PD/PK relationship. KFRX03 has a compelling safety profile with a strong therapeutic benefit in mice models of dementia.
Publications
Safety, Cognitive, and Behavioral Outcomes in Patients with Dementia with Lewy Bodies Treated with Nilotinib
C-KIT Inhibitors Reduce Pathology and Improve Behavior in the Tg(SwDI) Model of Alzheimer’s Disease
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease